Prevention

Why?

• Patients with LV dysfunction who receive prophylactic sotalol compared with placebo are at increased risk of dying. ^a

Sotalol increases mortality with heart failure

Patient	Treatment	Comparison	Outcome	CER	RRR (95% CI)	NNH (95% CI)
myocardial infarction and heart failure a	sotalol	placebo	death at 5 months	3.1%	65% (16% to 140%)	50 (30 to 170)